Abrocitinib Approved for Atopic Dermatitis in Europe

The oral JAK inhibitor was approved for treating AD earlier in 2021 for treating AD in the United Kingdom, Japan, and Korea, and is under review at the US Food and Drug Administration.

Related Keywords

Japan ,United Kingdom , ,Pfizer ,European Commission ,Drug Administration ,Medicinal Products ,Human Use ,European Medicines Agency ,Dermatitis ,Europe ,European ,Atopic Dermatitis ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,United Kingdom Site Content ,Antiretroviral Therapy ,Antiretroviral Therapy Art ,Art ,Atazanavir ,Darunavir ,Travirine ,Ipranavir ,Herapy Antiretroviral ,Hiv Infection ,Shiv ,Nucleoside Reverse Transcriptase Inhibitors ,Ucleoside Analog ,Artis ,Nhibitor Nuc ,